Structure Therapeutics (NASDAQ:GPCR) Given New $70.00 Price Target at HC Wainwright

Structure Therapeutics (NASDAQ:GPCR) had its price target reduced by equities researchers at HC Wainwright from $100.00 to $70.00 in a research note issued on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 68.55% from the stock’s current price.

A number of other brokerages have also recently commented on GPCR. Citizens Jmp reduced their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, Wolfe Research assumed coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $41.53 on Thursday. The stock has a market cap of $2.95 billion, a PE ratio of -47.74 and a beta of -1.35. Structure Therapeutics has a one year low of $15.80 and a one year high of $94.90. The stock has a fifty day moving average of $43.89 and a 200 day moving average of $57.21.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, sell-side analysts predict that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently made changes to their positions in GPCR. Sterling Capital Management LLC purchased a new stake in shares of Structure Therapeutics during the first quarter worth about $28,000. State of Wyoming purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $28,000. EverSource Wealth Advisors LLC grew its position in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC grew its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.